The New CRO Role: Will it Reverse Declining Patient Enrolment?

Apr 28, 2012

The cost of patient enrolment is now the single largest part of the total trial budget, representing 32% of the cost. Among CROs and sponsors, this expense has been accepted as the inevitable cost of trial management, but it no longer should be. Richard Malcolm of Acurian considers what impact the emerging CRO/sponsor strategic partnerships that represent the latest trend in the CRO industry will have on patient enrolment. ...

Read More

Optimised Commissioning of Control systems Pre-Parameterisation of Control Systems Facilitates their Planning and Commissioning

Apr 28, 2012

In the commissioning of control systems, coordination problems between the selected individual components occur quite frequently. Dr Egon Huefner, of B├╝rkert Fluid Control Systems, discusses a new, integrated controller concept with pre-parameterised control systems and defined components that prevents these problems and ensures fast, trouble-free commissioning. ...

Read More

Next-Generation Instrument Discovers Low Affinity Inhibitors of the Inositol Phosphate Pathway

Apr 28, 2012

Traditional high-throughput screening (HTS) strategies searching for single targets have not led to a high number of promising leads for new drugs. Hence pharmaceutical companies are now increasingly looking for multi-target drugs to investigate. Dr E J Dell of BMG LABTECH explains how a next-generation photomultiplier- (PMT-) based instrument was compared to a high-performance charged coupled device (CCD), and how a next-generation HTS microplate reader provides a new more economical tool for finding lower affinity drug discovery compounds via traditional HTS bioassays. ...

Read More

Unfolding the Science of Senescence

Apr 28, 2012

The ever ageing global population has led to an increasing prevalence of protein misfolding diseases, which underlie a number of serious and chronic degenerative conditions. The misshapen structures of these abnormal proteins make them aggregation-prone, leading to the formation of toxic aggregates that underlie various disease pathologies. As the details of the science of this process continue to unfold, new therapeutic approaches to combat this fundamental mechanism of senescence are now emerging. Dr Mark Treherne, Chief Executive at Senexis, explains that as our understanding of the science underlying this fundamental pathological process continues to evolve, we will come ever closer ...

Read More